Clinical Trial Detail

NCT ID NCT03690869
Title REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications

Advanced Solid Tumor

malignant glioma

central nervous system cancer

Therapies

Cemiplimab

Age Groups: child adult

No variant requirements are available.